Niagen Bioscience, Inc. (NAGE)
NASDAQ: NAGE · Real-Time Price · USD
6.96
+0.19 (2.73%)
Mar 31, 2025, 3:36 PM EDT - Market open
Niagen Bioscience Revenue
In the year 2024, Niagen Bioscience had annual revenue of $99.60M with 19.18% growth. Niagen Bioscience had revenue of $29.13M in the quarter ending December 31, 2024, with 37.41% growth.
Revenue (ttm)
$99.60M
Revenue Growth
+19.18%
P/S Ratio
5.16
Revenue / Employee
$957,663
Employees
104
Market Cap
541.92M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 99.60M | 16.03M | 19.18% |
Dec 31, 2023 | 83.57M | 11.52M | 15.99% |
Dec 31, 2022 | 72.05M | 4.60M | 6.82% |
Dec 31, 2021 | 67.45M | 8.19M | 13.82% |
Dec 31, 2020 | 59.26M | 12.97M | 28.01% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 30, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Jan 2, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
NAGE News
- 11 days ago - Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms - Business Wire
- 12 days ago - ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science - Business Wire
- 18 days ago - ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025 - Business Wire
- 19 days ago - ChromaDex to Present at the 37th Annual Roth Conference - Business Wire
- 25 days ago - ChromaDex Capitalizes On Longevity Boom But Valuation Remains High - Seeking Alpha
- 26 days ago - ChromaDex Corporation (CDXC) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 26 days ago - ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results - Business Wire
- 4 weeks ago - ChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 4, 2025 - Business Wire